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In The Lancet Infectious Diseases, Robert Aldridge 
and colleagues1 report ﬁ ndings from the UK migrant 
screening programme for tuberculosis, in which 
visa applicants are screened for tuberculosis before 
migration. This pre-migration screening covers 
people who are applying to travel to the UK with an 
intention to stay for more than 6 months and come 
from a country with a high incidence of tuberculosis. 
People intending to migrate to the UK are required to 
report to a clinic that has been approved by the Home 
Oﬃ  ce, and are then examined with chest radiography 
to exclude tuberculosis. Individuals identiﬁ ed with 
tuberculosis by the screening process will be given a 
visa only after completion of tuberculosis treatment, 
when they cease to be infectious, which lowers the risk 
for onward transmission in the UK. Such programmes 
are used to replace on-arrival screening. Migrants cover 
the costs of testing and treatment and, therefore, the 
host country can save health-care costs. Given these 
advantages, why shouldn’t all European countries 
implement pre-entry tuberculosis screening?2
First of all, pre-entry screening only covers regular 
planned migration; asylum seekers and irregular 
migrants are not included. Thus a pre-entry screening 
programme will need to be complemented by other 
measures to control tuberculosis in migrant groups 
that are not targeted by the programme, and it is, 
therefore, not the ultimate solution. Indeed, an 
important limitation of Aldridge and colleagues’ 
study,1 acknowledged by the authors, is that it did not 
include undocumented migrants. The recent inﬂ ux 
of irregular migrants and those applying for refugee 
status into the European Union raises an urgent 
question about infectious disease screening in this 
population, which cannot be addressed with pre-entry 
screening. In fact, compulsory pre-entry screening 
might provide incentive for irregular migration. 
Also, migrants coming from countries with a 
tuberculosis incidence below a prespeciﬁ ed threshold 
are not screened. In Aldridge and colleagues’s study,1 
individuals had to undergo pre-entry screening if the 
WHO-estimated tuberculosis incidence exceeded 
40 per 100 000 in their country of origin. The incidence 
rate cutoﬀ  that determines whether an individual 
needs to be screened seems to be an arbitrary choice. 
High-income countries vary in the choice of tuberculosis 
incidence rate in the migrants’ country of origin that 
they use to deﬁ ne target groups for screening (eg, 
from >15 cases per 100 000, to >40, >50, or >100 cases 
per 100 000).2 The question arises as to what criteria—
eg, the yield of screening, its cost-eﬀ ectiveness—should 
be used to set such threshold values. Whatever the 
choice of cutoﬀ  rate, tuberculosis cases will occur in 
migrants who are not subjected to screening. 
Second, no type of screening programme for 
active tuberculosis precludes the occurrence of 
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tuber culosis afterwards. Country level data show that 
in an important proportion of tuberculosis cases in 
migrants, tuberculosis is diagnosed more than 2 years 
after entry into the country.3,4 This ﬁ nding could be 
due to reactivation of latent tuberculosis infection, 
or trans mission in the host country. Also, chest 
radiography is not a perfect screening method, and a 
proportion of tuberculosis cases will not be identiﬁ ed 
during the screening process. 
Finally, published information about cost-eﬀ ective-
ness of pre-entry screening is scarce.5 Potential overall 
savings might be a result of shifting the screening (and 
treatment) costs to the country of origin. Whether this 
is a cost-eﬀ ective strategy depends on the perspective 
taken—ie, a country or global perspective, or health 
sector or societal perspective. 
We believe that tuberculosis in migrants needs 
attention if the goal of tuberculosis elimination is to 
be reached.6,7 Pre-entry screening programmes can 
be a useful component of a tuberculosis elimination 
strategy and can add to the control of tuberculosis 
in migrants; however, they do not cover all types 
of migrant populations, and tuberculosis will occur 
after screening. Therefore, as emphasised in a recent 
publication by the European Centre for Disease 
Prevention and Control, priority should be given to 
ensuring that health-care services are accessible and 
responsive to the needs of all, including migrants, so 
that they can ensure early diagnosis and treatment 
of incident tuberculosis in migrants6,8 and other 
potentially susceptible groups. This view is also 
advocated by the 2015–20 Collaborative Tuberculosis 
Strategy for England,9 which includes not only 
coordination of pre-entry screening, but also a strong 
focus on improving access to services and ensuring 
early diagnosis.
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Schistosomiasis transmission in Europe
Urogenital schistosomiasis caused by the trematode 
worm Schistosoma haematobium (along with intestinal 
and hepatic schistosomiasis caused by Schistosoma 
mansoni and other species) is acquired by bathing 
in freshwater colonised by a suitable intermediate 
host (a freshwater snail of the genus Bulinus).1 Widely 
diﬀ used in Africa and in areas of southeast Asia and 
Latin America, schistosomiasis is one of the most 
important neglected tropical diseases.1 Therefore, 
the recent outbreak of urogenital schistosomiasis in 
Corsica (France), came as a big surprise. The study by 
Jerome Boissier and colleagues in The Lancet Infectious 
Diseases2 provides a clue as to the origin of the French 
outbreak.
Previously, local transmission in Europe had 
only been recorded in Portugal, with the last cases 
diagnosed in the 1960s.3 About 50 years later, in the 
summer of 2013, several people were infected after 
bathing in the Cavu River in Corsica.4,5 The ﬁ rst cases 
were reported at the beginning of 2014. Interestingly, 
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